- Home
- AVDX vs NAMS Comparison
AVDX vs NAMS Comparison
Compare AVDX & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVDX
- NAMS
- Stock Information
- Founded
- AVDX 2000
- NAMS 2019
- Country
- AVDX United States
- NAMS Netherlands
- Employees
- AVDX N/A
- NAMS N/A
- Industry
- AVDX EDP Services
- NAMS Biotechnology: Pharmaceutical Preparations
- Sector
- AVDX Technology
- NAMS Health Care
- Exchange
- AVDX Nasdaq
- NAMS Nasdaq
- Market Cap
- AVDX 2.0B
- NAMS 2.2B
- IPO Year
- AVDX 2021
- NAMS N/A
- Fundamental
- Price
- AVDX $9.77
- NAMS $18.93
- Analyst Decision
- AVDX Hold
- NAMS Strong Buy
- Analyst Count
- AVDX 15
- NAMS 6
- Target Price
- AVDX $10.04
- NAMS $42.83
- AVG Volume (30 Days)
- AVDX 8.5M
- NAMS 689.2K
- Earning Date
- AVDX 05-07-2025
- NAMS 05-08-2025
- Dividend Yield
- AVDX N/A
- NAMS N/A
- EPS Growth
- AVDX N/A
- NAMS N/A
- EPS
- AVDX 0.01
- NAMS N/A
- Revenue
- AVDX $441,284,000.00
- NAMS $47,140,000.00
- Revenue This Year
- AVDX $5.73
- NAMS N/A
- Revenue Next Year
- AVDX $10.25
- NAMS N/A
- P/E Ratio
- AVDX $1,092.72
- NAMS N/A
- Revenue Growth
- AVDX 10.46
- NAMS 586.97
- 52 Week Low
- AVDX $6.61
- NAMS $14.06
- 52 Week High
- AVDX $12.93
- NAMS $27.29
- Technical
- Relative Strength Index (RSI)
- AVDX 72.60
- NAMS 54.33
- Support Level
- AVDX $8.12
- NAMS $16.95
- Resistance Level
- AVDX $9.81
- NAMS $19.58
- Average True Range (ATR)
- AVDX 0.03
- NAMS 0.96
- MACD
- AVDX -0.04
- NAMS -0.03
- Stochastic Oscillator
- AVDX 55.56
- NAMS 76.20
About AVDX AvidXchange Holdings Inc.
AvidXchange Holdings Inc is a provider of AP automation software and payment solutions for middle-market businesses and their suppliers. It generates the majority of its sales from Payment revenue followed by Software revenue and Services revenue. The company generates revenue in the United States.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.